In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d

被引：0
|
作者：
Schectman, Joel M. M. [1 ]
机构：
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22903 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 02期
关键词：
D O I：
10.7326/J22-0118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Eikelboom JW, Jolly SS, Belley-Cote EP, et al.Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised,controlled trial.Lancet Respir Med. 2022;10:1160-8
引用
收藏
页码：JC17 / JC17
页数：1
相关论文
共 50 条
  • [1] In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d
    Mourad, Omar
    Chagla, Zain
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (05) : JC50 - JC50
  • [2] Remdesivir (Veklury) in High-Risk Outpatients with COVID-19
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1644): : 31 - 32
  • [3] Early Convalescent Plasma for High-Risk Outpatients with Covid-19
    Korley, Frederick K.
    Durkalski-Mauldin, Valerie
    Yeatts, Sharon D.
    Schulman, Kevin
    Davenport, Robertson D.
    Dumont, Larry J.
    El Kassar, Nahed
    Foster, Lydia D.
    Hah, Jennifer M.
    Jaiswal, Siddartha
    Kaplan, Alesia
    Lowell, Ezekiel
    McDyer, John F.
    Quinn, James
    Triulzi, Darrell J.
    Van Huysen, Carol
    Stevenson, Valerie L. W.
    Yadav, Kabir
    Jones, Christopher W.
    Kea, Bory
    Burnett, Aaron
    Reynolds, Joshua C.
    Greineder, Colin F.
    Haas, Nathan L.
    Beiser, David G.
    Silbergleit, Robert
    Barsan, William
    Callaway, Clifton W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21): : 1951 - 1960
  • [4] Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
    Lee, Ji Yeon
    Lee, Jee Young
    Ko, Jae-Hoon
    Hyun, Miri
    Kim, Hyun Ah
    Cho, Seongcheol
    Lee, Yong Dae
    Song, Junghoon
    Shin, Seunghwan
    Peck, Kyong Ran
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19
    Fox, Matthew P.
    D'Agostino McGowan, Lucy
    James, Bryan D.
    Lessler, Justin
    Mehta, Shruti H.
    Murray, Eleanor J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2021, 190 (04) : 491 - 495
  • [6] Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
    Dryden-Peterson, Scott
    Kim, Andy
    Joyce, Mary-Ruth
    Johnson, Jennifer A.
    Kim, Arthur Y.
    Baden, Lindsey R.
    Woolley, Ann E.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (11):
  • [7] Chronic rhinosinusitis was neither a risk nor a protective factor during the COVID-19 pandemic
    Gudziol, Hilmar
    Hummel, Thomas
    Guntinas-Lichius, Orlando
    HNO, 2025, 73 (02) : 129 - 135
  • [8] Is Plasma Therapy useful in High-Risk Patients with severe COVID-19 Progression?
    Lichert, Frank
    TRANSFUSIONSMEDIZIN, 2023, 13 (02) : 72 - 73
  • [9] Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease
    Dai, Zhenyu
    Zeng, Dong
    Cui, Dawei
    Wang, Dawei
    Feng, Yanling
    Shi, Yuhan
    Zhao, Liangping
    Xu, Jingjing
    Guo, Wenjuan
    Yang, Yuexiang
    Zhao, Xinguo
    Li, Duoduo
    Zheng, Ye
    Wang, Ao
    Wu, Minmin
    Song, Shu
    Lu, Hongzhou
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [10] Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
    Bruno, Giuseppe
    Giotta, Massimo
    Perelli, Serena
    De Vita, Giuseppina
    Bartolomeo, Nicola
    Buccoliero, Giovanni Battista
    VIRUSES-BASEL, 2022, 14 (11):
12345